Literature DB >> 26666305

Molecular and genomic characterization of pathogenic traits of group A Streptococcus pyogenes.

Shigeyuki Hamada1, Shigetada Kawabata, Ichiro Nakagawa.   

Abstract

Group A streptococcus (GAS) or Streptococcus pyogenes causes various diseases ranging from self-limiting sore throat to deadly invasive diseases. The genome size of GAS is 1.85-1.9 Mb, and genomic rearrangement has been demonstrated. GAS possesses various surface-associated substances such as hyaluronic capsule, M proteins, and fibronectin/laminin/immunoglobulin-binding proteins. These are related to the virulence and play multifaceted and mutually reflected roles in the pathogenesis of GAS infections. Invasion of GAS into epithelial cells and deeper tissues provokes immune and non-immune defense or inflammatory responses including the recruitment of neutrophils, macrophages, and dendritic cells in hosts. GAS frequently evades host defense mechanisms by using its virulence factors. Extracellular products of GAS may perturb cellular and subcellular functions and degrade tissues enzymatically, which leads to the aggravation of local and/or systemic disorders in the host. In this review, we summarize some important cellular and extracellular substances that may affect pathogenic processes during GAS infections, and the host responses to these.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26666305      PMCID: PMC4773581          DOI: 10.2183/pjab.91.539

Source DB:  PubMed          Journal:  Proc Jpn Acad Ser B Phys Biol Sci        ISSN: 0386-2208            Impact factor:   3.493


  141 in total

1.  Structural basis for HLA-DQ binding by the streptococcal superantigen SSA.

Authors:  E Sundberg; T S Jardetzky
Journal:  Nat Struct Biol       Date:  1999-02

2.  Group A Streptococcus induces apoptosis in human epithelial cells.

Authors:  P J Tsai; Y S Lin; C F Kuo; H Y Lei; J J Wu
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

3.  Capsular hyaluronic acid of group A streptococci hampers their invasion into human pharyngeal epithelial cells.

Authors:  S Kawabata; H Kuwata; I Nakagawa; S Morimatsu; K Sano; S Hamada
Journal:  Microb Pathog       Date:  1999-08       Impact factor: 3.738

4.  Systemic and mucosal immunizations with fibronectin-binding protein FBP54 induce protective immune responses against Streptococcus pyogenes challenge in mice.

Authors:  S Kawabata; E Kunitomo; Y Terao; I Nakagawa; K Kikuchi; K Totsuka ; S Hamada
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

5.  Complete genome sequence of an M1 strain of Streptococcus pyogenes.

Authors:  J J Ferretti; W M McShan; D Ajdic; D J Savic; G Savic; K Lyon; C Primeaux; S Sezate; A N Suvorov; S Kenton; H S Lai; S P Lin; Y Qian; H G Jia; F Z Najar; Q Ren; H Zhu; L Song; J White; X Yuan; S W Clifton; B A Roe; R McLaughlin
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-10       Impact factor: 11.205

6.  Cytochrome c-mediated caspase-9 activation triggers apoptosis in Streptococcus pyogenes-infected epithelial cells.

Authors:  I Nakagawa; M Nakata; S Kawabata; S Hamada
Journal:  Cell Microbiol       Date:  2001-06       Impact factor: 3.715

Review 7.  Pathogenesis of group A streptococcal infections.

Authors:  M W Cunningham
Journal:  Clin Microbiol Rev       Date:  2000-07       Impact factor: 26.132

8.  CD44 as a receptor for colonization of the pharynx by group A Streptococcus.

Authors:  C Cywes; I Stamenkovic; M R Wessels
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

9.  SclA, a novel collagen-like surface protein of Streptococcus pyogenes.

Authors:  M Rasmussen; A Edén; L Björck
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

10.  emm typing and validation of provisional M types for group A streptococci.

Authors:  R Facklam; B Beall; A Efstratiou; V Fischetti; D Johnson; E Kaplan; P Kriz; M Lovgren; D Martin; B Schwartz; A Totolian; D Bessen; S Hollingshead; F Rubin; J Scott; G Tyrrell
Journal:  Emerg Infect Dis       Date:  1999 Mar-Apr       Impact factor: 6.883

View more
  6 in total

1.  A Red Blood Cell Membrane-Camouflaged Nanoparticle Counteracts Streptolysin O-Mediated Virulence Phenotypes of Invasive Group A Streptococcus.

Authors:  Tamara Escajadillo; Joshua Olson; Brian T Luk; Liangfang Zhang; Victor Nizet
Journal:  Front Pharmacol       Date:  2017-07-18       Impact factor: 5.810

Review 2.  Streptococcus pyogenes-purpura fulminans as an invasive form of group A streptococcal infection.

Authors:  Sayaka Okuzono; Masataka Ishimura; Shunsuke Kanno; Motoshi Sonoda; Noriyuki Kaku; Yoshitomo Motomura; Hisanori Nishio; Utako Oba; Masuo Hanada; Jun-Ichi Fukushi; Michiyo Urata; Dongchon Kang; Hidetoshi Takada; Shouichi Ohga
Journal:  Ann Clin Microbiol Antimicrob       Date:  2018-07-09       Impact factor: 3.944

3.  Micro-evolution of three Streptococcus species: selection, antigenic variation, and horizontal gene inflow.

Authors:  Pavel V Shelyakin; Olga O Bochkareva; Anna A Karan; Mikhail S Gelfand
Journal:  BMC Evol Biol       Date:  2019-03-27       Impact factor: 3.260

4.  Sickening or Healing the Heart? The Association of Ficolin-1 and Rheumatic Fever.

Authors:  Sandra Jeremias Catarino; Fabiana Antunes Andrade; Angelica Beate Winter Boldt; Luiza Guilherme; Iara Jose Messias-Reason
Journal:  Front Immunol       Date:  2018-12-18       Impact factor: 7.561

5.  Streptococcus pyogenes Transcriptome Changes in the Inflammatory Environment of Necrotizing Fasciitis.

Authors:  Yujiro Hirose; Masaya Yamaguchi; Daisuke Okuzaki; Daisuke Motooka; Hiroshi Hamamoto; Tomoki Hanada; Tomoko Sumitomo; Masanobu Nakata; Shigetada Kawabata
Journal:  Appl Environ Microbiol       Date:  2019-10-16       Impact factor: 4.792

6.  Effects of artificial honey and epigallocatechin-3-gallate on streptococcus pyogenes.

Authors:  Song Chen; Ruijie Huang; Xiaoge Jiang; An Lin; Shijia Li; Yangyang Shi; Fangjie Zhou; Grace Gomez Felix Gomez; Richard L Gregory; Chaoliang Zhang
Journal:  BMC Microbiol       Date:  2022-08-26       Impact factor: 4.465

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.